DARE NASDAQ
Dare Bioscience, Inc.
1W: +8.7%
1M: +13.9%
3M: -59.5%
YTD: -56.8%
1Y: -60.8%
3Y: -84.7%
5Y: -95.9%
$0.84
-0.01 (-0.96%)
Weekly Expected Move ±8.9%
$1
$1
$1
$1
$1
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
12 relationships12
As Filer
counterparties named
0
As Counterparty
mentioned by others
3
Rel. Types
2021-07-12
Earliest Filing
2024-10-21
Latest Filing
partner: 8
investor: 3
target: 1
Counterparties (Filed by DARE)
12 relationshipsCompanies named in DARE's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| DARÉ BIOSCIENCE, INC. | — | target | Company selling common stock to investor | 2024-10-21 | View |
| LINCOLN PARK CAPITAL FUND, LLC | — | investor | Investor purchasing up to $15,000,000 of common stock | 2024-10-21 | View |
| XOMA (US) LLC | — | investor | Counterparty in royalty monetization transaction providing $22 million financing | 2024-04-30 | View |
| Organon | OGN | partner | Licensee of XACIATO under global license agreement with Daré | 2024-04-30 | View |
| Bayer | BYMOF | partner | Licensee of Ovaprene under license agreement with Daré | 2024-04-30 | View |
| United in Endeavour, LLC | — | investor | Counterparty in existing royalty interest financing agreement | 2024-04-30 | View |
| Organon | OGN | partner | Commercial collaborator and licensee for XACIATO global launch | 2023-07-05 | View |
| Bayer | BYMOF | partner | Licensee for U.S. commercial rights to Ovaprene | 2023-07-05 | View |
| Stifel, Nicolaus & Company, Incorporated | — | partner | Agent for the sale of Placement Shares | 2023-03-31 | View |
| Cantor Fitzgerald & Co. | — | partner | Agent for the sale of Placement Shares | 2023-03-31 | View |
| SVB Leerink LLC | — | partner | Entered into a sales agreement to act as agent for an at-the-market equity offering program. | 2021-10-13 | View |
| Health Decisions Inc. | — | partner | Contract research organization providing clinical coordination and data collection services for the CRADA study. | 2021-07-12 | View |
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-10-02 | Delisting Notice | View | |
| 2026-10-01 | Regulation FD; Exhibits | View | |
| 2026-09-11 | Bylaws Amendment | View | |
| 2026-09-09 | Regulation FD; Exhibits | View | |
| 2026-08-17 | Material Agreement; Unregistered Equity Sales; Other Events; Exhibits | Agreement | View |
| 2026-08-13 | Earnings Release; Exhibits | View | |
| 2026-07-24 | Regulation FD; Exhibits | View | |
| 2026-07-17 | Delisting Notice | View | |
| 2026-07-13 | Regulation FD; Exhibits | View | |
| 2026-06-22 | Regulation FD; Exhibits | View | |
| 2026-06-12 | Officer/Director Change; Shareholder Vote; Exhibits | View | |
| 2026-05-18 | Unregistered Equity Sales | View | |
| 2026-05-07 | Unregistered Equity Sales | View | |
| 2026-04-22 | Regulation FD; Exhibits | View | |
| 2026-04-20 | Unregistered Equity Sales | View | |
| 2026-04-17 | Officer/Director Change | View | |
| 2026-04-13 | Unregistered Equity Sales | View | |
| 2026-03-26 | Earnings Release; Exhibits | View | |
| 2026-03-17 | Unregistered Sales of Equity Securities | View | |
| 2026-03-09 | Unregistered Sales of Equity Securities | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR